Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
January 12 2024 - 5:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2024
Commission file number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into English)
The Circle 6
8058 Zurich, Switzerland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On
January 12, 2024, NLS Pharmaceutics Ltd., or the Registrant, issued a press release titled: “NLS Pharmaceutics Announces Receipt
of Notice of Deficiency with Nasdaq Continued Listing Requirements.” A copy of this press release is furnished herewith as Exhibit
99.1.
This
report is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-262489, and 333-268690
and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
NLS Pharmaceutics Ltd. |
|
|
|
Date: January 12, 2024 |
By: |
/s/ Alexander Zwyer |
|
|
Name: |
Alexander Zwyer |
|
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
![Logo
Description automatically generated with low confidence](https://www.sec.gov/Archives/edgar/data/1783036/000121390024003419/image_001.jpg)
NLS
Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
Zürich,
Switzerland, January 12, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”),
a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare
and complex central nervous system disorders, today announced that on January 9, 2024, it received
a letter from the Listing Qualifications staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that it is no longer
in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule
5550(b)(1) requires listed companies to maintain stockholders' equity of at least $2,500,000. In accordance with Nasdaq Marketplace Rule
5810(c)(2)(A), the Company has 45 calendar days, or until February 23, 2024, to submit a plan to regain compliance. If the plan is accepted,
Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. The notification letter
has no immediate effect on the Company's listing on the Nasdaq Capital Market. The Company’s management is looking into
various options available to regain compliance and maintain its continued listing on the Nasdaq Capital Market. The Company intends to
submit the compliance plan as soon as practicable.
About
NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd.
(Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and
internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex
central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led
by an experienced management team with a track record of developing and commercializing product candidates. For more information, please
visit www.nlspharma.com.
Safe Harbor Statement
This letter contains
expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For
example, NLS is using forward-looking statements when it discusses the potential to regain compliance with Nasdaq's continued listing
requirements, and the timing and effect thereof. These forward-looking statements and their implications are based on the current
expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results
to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter
delays or obstacles in launching and/or successfully completing its clinical trials; NLS’ products may not be approved by regulatory
agencies, NLS’ technology may not be validated as it progresses further and its methods may not be accepted by the scientific community;
NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific
difficulties may develop with NLS’ process; NLS’ products may wind up being more expensive than it anticipates; results in
the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate
with the results of human clinical trials; NLS’ patents may not be sufficient; NLS’ products may harm recipients; changes
in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss
of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ
materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation
to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained
under the heading “Risk Factors” in NLS’ annual report on Form 20-F for the year ended December 31, 2022 filed with
the Securities and Exchange Commission (“SEC”), which is available on the SEC’s website, www.sec.gov, and in subsequent
filings made by NLS with the SEC.
For additional
information:
Marianne Lambertson
(investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharmaceutics.com
###
NLS Pharmaceutics (NASDAQ:NLSP)
Historical Stock Chart
From Jul 2024 to Aug 2024
NLS Pharmaceutics (NASDAQ:NLSP)
Historical Stock Chart
From Aug 2023 to Aug 2024